Business Strategy
In summary, Renovo’s business strategy is to:
- Leverage extensive scientific knowledge to develop commercial product candidates in scar reduction
- Be first-to-market with a pharmaceutical product to reduce scarring
- Continue to advance and expand the Company's deep clinical and pre-clinical pipeline
- Extend the significant market potential for the Company's lead product candidates to multiple body sites
- Pursue a commercialisation strategy working with commercialisation partners to increase speed and depth of market penetration
Extensive scientific knowledge in scar reduction
The founders, Professor Mark Ferguson, CEO, and Dr Sharon O'Kane together with their associated research groups, are international leaders in research on scarring and have been responsible for extensive related scientific investigations since 1984. This work has allowed Renovo to generate a significant pipeline of product candidates, with Juvista, Adaprev, Prevascar and Juvidex in Phase 3 and 2 clinical trials and numerous candidates in development.
Be first-to-market with a pharmaceutical product to reduce scarring
According to The Mattson Jack Group, an independent research group, the US commercial market for reduction of scarring in the skin is valued at approximately US$4 billion per annum. There are some 42 million patients each year who could potentially benefit from pharmaceuticals that prevent or reduce scarring in the skin. This market is larger in patient volume than Depression, Osteoporosis, Asthma and Diabetes.
Skin: Amongst the largest US Markets
Currently there are no related pharmaceuticals available in the market either in the US or Europe. Renovo plans to be the first internationally to launch a marketed pharmaceutical drug for the reduction of scarring.
Broaden the comprehensive clinical and pre-clinical pipeline
Renovo has a robust product candidate pipeline. In addition to Juvista, we have three further product candidates - Adaprev, Prevascar and Juvidex - each with different mechanisms of action and at various stages of Phase 2 clinical trials.
The company has a strong portfolio of intellectual property, with more than 500 granted patents and patent applications worldwide, as well as a number of exclusive licensing agreements which allow access to the key patents required for the development of Renovo's lead drug candidates.
Established in-house Phase 1 and Phase 2 clinical trials
Anti-scarring and wound healing accelerant therapies arising from Renovo’s discovery programmes are developed up to and including Phase 2 human clinical trials in house. The company has constructed and staffed its own clinical trials unit capable of operating around the clock to rapidly develop its potential new drugs. The unit is externally monitored to ensure that it operates to the highest international standards. Typically, Renovo has several clinical trials running at any one time.
External Phase 2 and Phase 3 clinical trials
Renovo's leading drugs to reduce scarring are undergoing rigorous clinical trials in a variety of appropriate clinical patients. These patient-based trials are conducted internationally by leading surgeons and physicians.
|
